Gena Wang

Stock Analyst at Barclays

(3.78)
# 897
Out of 4,495 analysts
136
Total ratings
43.02%
Success rate
10.53%
Average return

29 Stocks

Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Overweight
Price Target: $236$291
Current: $236.70
Upside: +22.94%
Sarepta Therapeutics
Jun 21, 2024
Maintains: Overweight
Price Target: $185$226
Current: $143.78
Upside: +57.18%
Solid Biosciences
May 16, 2024
Maintains: Overweight
Price Target: $21$18
Current: $7.80
Upside: +130.77%
Editas Medicine
May 9, 2024
Maintains: Equal-Weight
Price Target: $11$9
Current: $5.30
Upside: +69.81%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Equal-Weight
Price Target: $80$67
Current: $56.21
Upside: +19.20%
Beam Therapeutics
May 8, 2024
Maintains: Equal-Weight
Price Target: $42$33
Current: $25.46
Upside: +29.62%
4D Molecular Therapeutics
Apr 15, 2024
Initiates: Overweight
Price Target: $45
Current: $15.14
Upside: +197.23%
Kodiak Sciences
Apr 1, 2024
Maintains: Underweight
Price Target: $2$3
Current: $3.00
Upside: -
REGENXBIO
Mar 7, 2024
Maintains: Overweight
Price Target: $45$55
Current: $12.85
Upside: +328.02%
Vertex Pharmaceuticals
Feb 6, 2024
Maintains: Overweight
Price Target: $446$472
Current: $488.12
Upside: -3.30%
Legend Biotech
Jan 24, 2024
Maintains: Overweight
Price Target: $93$94
Current: $58.24
Upside: +61.40%
BioMarin Pharmaceutical
Nov 2, 2023
Maintains: Overweight
Price Target: $125$111
Current: $83.34
Upside: +33.19%
PTC Therapeutics
Oct 27, 2023
Maintains: Equal-Weight
Price Target: $26$25
Current: $32.81
Upside: -23.80%
Sangamo Therapeutics
Aug 9, 2023
Maintains: Overweight
Price Target: $11$9
Current: $0.40
Upside: +2,132.70%
Intellia Therapeutics
Aug 7, 2023
Maintains: Overweight
Price Target: $86$90
Current: $26.09
Upside: +244.96%
Vir Biotechnology
Jul 21, 2023
Maintains: Overweight
Price Target: $59$41
Current: $10.22
Upside: +301.17%
bluebird bio
Jun 1, 2023
Upgrades: Overweight
Price Target: $7$8
Current: $1.15
Upside: +595.65%
Ionis Pharmaceuticals
May 4, 2023
Maintains: Equal-Weight
Price Target: $40$37
Current: $47.33
Upside: -21.83%
Zymeworks
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7$9
Current: $9.81
Upside: -8.26%
Arcturus Therapeutics Holdings
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16$25
Current: $23.42
Upside: +6.75%
BioCryst Pharmaceuticals
Aug 5, 2022
Maintains: Equal-Weight
Price Target: $12$14
Current: $7.05
Upside: +98.58%
Cellectis
May 13, 2022
Maintains: Overweight
Price Target: $9$7
Current: $2.16
Upside: +224.07%
MeiraGTx Holdings
May 13, 2022
Maintains: Overweight
Price Target: $32$18
Current: $4.67
Upside: +285.44%
ContextLogic
Nov 17, 2021
Maintains: Overweight
Price Target: n/a
Current: $6.03
Upside: -
Moderna
Nov 5, 2021
Maintains: Overweight
Price Target: n/a
Current: $121.32
Upside: -
Axonics
Aug 6, 2021
Maintains: Overweight
Price Target: n/a
Current: $68.00
Upside: -
Ultragenyx Pharmaceutical
Aug 3, 2021
Maintains: Overweight
Price Target: n/a
Current: $42.78
Upside: -
Puma Biotechnology
Nov 2, 2018
Downgrades: Underweight
Price Target: n/a
Current: $3.70
Upside: -
Abeona Therapeutics
Jan 6, 2017
Initiates: Buy
Price Target: n/a
Current: $5.04
Upside: -